Form 4 for CADL Candel Therapeutics, Inc.
Accepted 2026-02-26 00:00:00 ET · period of report 2026-02-23 · accession 0001193125-26-078246 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2026-02-26 | 2026-02-23 | CADL | Manning Paul B | Dir | P - Purchase | $5.45 | +550.5K | 2.76M | +25% | +$3.00M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-23 | P | A | 550,458 | $5.45 | 2,763,527 | I By Paul B. Manning Revocable Trust | — | — | (F1) The shares are held by The Paul B. Manning Revocable Trust dated May 10, 2000 (the "Trust"). The Reporting Person is the trustee of the Trust and has sole voting and investment power with respect to the shares held by the Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. |